Details for Patent: 11,793,796
✉ Email this page to a colleague
Which drugs does patent 11,793,796 protect, and when does it expire?
Patent 11,793,796 protects ZORYVE and is included in two NDAs.
This patent has forty patent family members in thirteen countries.
Summary for Patent: 11,793,796
| Title: | Inhibition of crystal growth of roflumilast |
| Abstract: | Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment. |
| Inventor(s): | David W. Osborne |
| Assignee: | Arcutis Biotherapeutics Inc |
| Application Number: | US17/102,056 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,793,796 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; Delivery; Dosage form; |
Drugs Protected by US Patent 11,793,796
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis | ZORYVE | roflumilast | CREAM;TOPICAL | 215985-002 | Jul 9, 2024 | RX | Yes | Yes | 11,793,796 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Arcutis | ZORYVE | roflumilast | CREAM;TOPICAL | 215985-001 | Jul 29, 2022 | RX | Yes | Yes | 11,793,796 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Arcutis | ZORYVE | roflumilast | CREAM;TOPICAL | 215985-003 | Oct 4, 2025 | RX | Yes | Yes | 11,793,796 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Arcutis | ZORYVE | roflumilast | FOAM;TOPICAL | 217242-001 | Dec 15, 2023 | RX | Yes | Yes | 11,793,796 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,793,796
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018282098 | ⤷ Start Trial | |||
| Australia | 2021214399 | ⤷ Start Trial | |||
| Brazil | 112019025748 | ⤷ Start Trial | |||
| Brazil | 112022015104 | ⤷ Start Trial | |||
| Canada | 3006836 | ⤷ Start Trial | |||
| Canada | 3150222 | ⤷ Start Trial | |||
| Canada | 3166300 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
